Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658480 | 0.97 | ACHE (0.47) | ACHESMN1; SMN2CHRM5ADRA2CHTR4 | |
| SCHEMBL19658487 | 0.95 | ACHE (0.50) | ACHESMN1; SMN2CHRM5ADRA2CHTR4 | |
| SCHEMBL12010818 | 0.89 | CHRM5 (0.46) | ACHESMN1; SMN2CHRM5ADRA2CHRH3 | |
| SCHEMBL19658599 | 0.86 | KDM4E (0.40) | ACHEHTR4 | |
| SCHEMBL12010842 | 0.86 | HRH3 (0.44) | ACHESMN1; SMN2CHRM5ADRA2CHRH3 | |
| SCHEMBL19658670 | 0.84 | MGLL (0.39) | ACHESMN1; SMN2HTR4HRH3 | |
| SCHEMBL19652172 | 0.83 | ACHE (0.40) | ACHESMN1; SMN2CHRM5ADRA2CHTR4 | |
| SCHEMBL14530950 | 0.81 | SMN1; SMN2 (0.46) | ACHESMN1; SMN2 | |
| SCHEMBL19658604 | 0.81 | NAMPT (0.39) | ACHEHTR4 | |
| SCHEMBL19658488 | 0.80 | ACHE (0.44) | ACHESMN1; SMN2CHRM5ADRA2CHTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | ACHE 2649/4885SMN1; SMN2 1221/4885CHRM5 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.